07:46:17 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-12 X-dag ordinarie utdelning PHI 0.00 SEK
2024-09-16 Kvartalsrapport 2025-Q1
2024-06-26 Bokslutskommuniké 2024
2024-03-27 Kvartalsrapport 2024-Q3
2023-12-21 Kvartalsrapport 2024-Q2
2023-11-15 Extra Bolagsstämma 2024
2023-10-27 Årsstämma 2024
2023-10-13 X-dag ordinarie utdelning PHI 0.00 SEK
2023-09-20 Kvartalsrapport 2024-Q1
2023-06-23 Bokslutskommuniké 2023
2023-05-09 Extra Bolagsstämma 2023
2023-03-28 Kvartalsrapport 2023-Q3
2022-12-21 Kvartalsrapport 2023-Q2
2022-10-31 Årsstämma 2023
2022-10-14 X-dag ordinarie utdelning PHI 0.00 SEK
2022-09-29 Kvartalsrapport 2023-Q1
2022-06-29 Bokslutskommuniké 2022
2022-03-21 Kvartalsrapport 2022-Q3
2022-03-15 Extra Bolagsstämma 2022
2021-12-29 Kvartalsrapport 2022-Q2
2021-10-20 Extra Bolagsstämma 2021
2021-10-11 X-dag ordinarie utdelning PHI 0.00 SEK
2021-09-29 Kvartalsrapport 2022-Q1
2021-06-24 Bokslutskommuniké 2021
2021-03-16 Kvartalsrapport 2021-Q3
2020-12-14 Kvartalsrapport 2021-Q2
2020-10-20 Årsstämma 2021
2020-10-15 X-dag ordinarie utdelning PHI 0.00 SEK
2020-09-28 Kvartalsrapport 2021-Q1
2020-06-25 Bokslutskommuniké 2020
2020-03-12 Kvartalsrapport 2020-Q3
2019-12-17 Kvartalsrapport 2020-Q2
2019-10-16 X-dag ordinarie utdelning PHI 0.00 SEK
2019-10-15 Årsstämma 2020
2018-09-27 X-dag ordinarie utdelning PHI 0.00 SEK
2018-09-26 Årsstämma 2019
2018-06-18 Extra Bolagsstämma 2019
2018-06-12 Bokslutskommuniké 2018
2018-03-12 Kvartalsrapport 2018-Q3
2017-09-26 X-dag ordinarie utdelning PHI 0.00 SEK
2017-09-25 Årsstämma 2018
2017-09-11 Kvartalsrapport 2018-Q1
2017-06-19 Bokslutskommuniké 2017
2017-03-13 Kvartalsrapport 2017-Q3
2017-01-01 Extra Bolagsstämma 2018
2016-11-30 Kvartalsrapport 2017-Q2
2016-09-06 X-dag ordinarie utdelning PHI 0.00 SEK
2016-09-05 Kvartalsrapport 2017-Q1
2016-09-05 Årsstämma 2017
2016-06-13 Bokslutskommuniké 2016
2016-02-22 Kvartalsrapport 2016-Q3
2016-02-16 Extra Bolagsstämma 2017
2015-11-30 Kvartalsrapport 2016-Q2
2015-09-08 X-dag ordinarie utdelning PHI 0.00 SEK
2015-09-07 Kvartalsrapport 2016-Q1
2015-09-07 Årsstämma 2016
2015-06-16 Bokslutskommuniké 2015
2015-03-16 Kvartalsrapport 2015-Q3
2014-12-01 Kvartalsrapport 2015-Q2
2014-10-07 X-dag ordinarie utdelning PHI 0.00 SEK
2014-10-06 Årsstämma 2015
2014-10-06 Kvartalsrapport 2015-Q1
2014-06-30 Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Phase Holographic Imaging PHI är verksamt inom medicinteknik. Bolaget utvecklar instrument och mjukvara för time-lapse cytometri. Produkterna används för kvantitativ långtidsanalys av levande cellers dynamik, särskilt av betydelse inom cancerforskning, samt vid behandling av inflammatoriska - samt autoimmuna sjukdomar. Produkterna säljs på global nivå via bolagets distributörer och störst närvaro återfinns inom Norden. Huvudkontoret ligger i Lund.
2024-06-11 09:32:20

Phase Holographic Imaging (PHI) is excited to announce a strategic partnership with University College London (UCL). Under this collaboration, PHI will lend a HoloMonitor® M4FL system for use in an ongoing research project at UCL, which runs alongside a clinical trial. This partnership represents PHI's first direct step in a hospital setting to explore the clinical applications of its innovative technology.

Patrik Eschricht, CEO of PHI, comments:

"Our HoloMonitor system provides detailed cell information to assess the quality of individual cell samples. Imagine a future where researchers can take a patient's cell sample at the bedside in the hospital and instantly determine its suitability for a clinical trial or cell therapy manufacturing. I believe this is the potential that our cell analysis technology holds.

Imagine, if this is possible, our technology could optimize the efficiency of clinical trials and cell therapy manufacturing processes, reduce costs, and make regenerative medicine more accessible and affordable-we would not use a cell therapy production site to manufacture a treatment that won't work and would not spend money on samples that won't be good enough."

PHI has partnered with UCL, a leading academic institution in England, to provide its latest live cell imaging system, HoloMonitor® M4FL. Through this partnership, PHI takes an active first step in further investigating this enormous potential market in which HoloMonitor products could be positioned directly at patient bedsides in hospitals-however, acknowledging that understanding the full possibilities is still at a very early stage.

"I'm very pleased with our new collaboration with UCL, which allows us to explore more the possibilities of our QPI technology for clinical applications and understand how it could make advanced regenerative treatments more accessible and cost-effective," Eschricht added.